Concepedia

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O’Nions, D. Peters, Christine M. McMahon, Ronan Swords, Rachel C. Cook, Jennifer N. Saultz, Jeffrey Tyner,

Blood · 2024 · 30 citations · 17 references

DOI

Concepts

Abstract

ABSTRACT: The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

References

17

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text

, , +14

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum et al. · Blood · 2022 · 3K citations · Full text

, , +17

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri et al. · Blood · 2020 · 649 citations · Full text

, , +9

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke et al. · Nature Cancer · 2020 · 203 citations · Full text

, , +16

Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat et al. · American Journal of Hematology · 2024 · 202 citations · Full text

, , +14